Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.
The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.
hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.
Revenue from the contract is primarily expected to be recognised in 2026.
IN-002 uses Inhalon's inhaled drug delivery platform.
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
Workflow Services completes one-year pilot and expands Colorectal Cancer Screening Education Program
RedHill Biopharma to submit Talicia for UK marketing authorisation
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
BiBBInstruments successfully demonstrates EndoDrill GI in live biopsy procedure
Evommune enrols first patient in EVO301 Phase 2 trial
Telix Pharmaceuticals' Illuccix approved in Brazil
Physiomics secures GBP102,000 contract with UK biotech for ADC therapy development
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer